Phase II Study of neoadjuvant chemotherapy with carboplatin,pemetrexed and bevacizumab in patients with non-squemous non-small-cell lung cancer
- Conditions
- on-squamous,non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000006759
- Lead Sponsor
- niversity of Tsukuba, Faculty of Medicine, Department of Thoracic Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Not provided
1)Uncontrolled infection or Serious medical complications 2)Uncontrollable diabetes mellitus 3)Uncontrollable hypertension 4)Therapeutic anticoagulopathy (except Aspirin within 325mg/day) 5)Current or previous history of hemoptysis 6)Evidence of bleeding diathesis or hemoptysis 7)With great vessel invasion 8)Cavity in tumor 9)Uncontrollable gastrointestinal ulceration 10)Current or previous(within the last 1 year) history of GI perforration 11)History of severe heart disease 12)Interstitial pneumonia or pulmonary fibrosis detectableon chest X-ray 13)Multiple primary cancer 14)With a history of drug sensitivity 15)Patients who do not want to take vitamin preparation 16)Serious psychiatric illness or psychological symptom 17)Women who are pregnant, lactating or with childbearing potential 18)Ineligible based on decision of an investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Down staging rate
- Secondary Outcome Measures
Name Time Method 2year survival rate,2-years relapse free survival,Progression free survival,rate of completion of the protocol treatment,Pathologic complete response rate,Complete resection rate,Safety